Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15:1073:80-89. doi: 10.1016/j.jchromb.2017.12.008. Epub 2017 Dec 6.

Abstract

Coproporphyrins are proposed as endogenous biomarkers of hepatic Organic Anion Transporting Polypeptide (OATP)1B functional activity. In this study, a new sample extraction method based on a mixed-mode anion exchange sorbent (SPE clean-up using Oasis 30mg Max 96 well plates) was developed for absolute quantification of coproporphyrin I and III (CP-I and CP-III) in human plasma. Chromatographic separation was performed with an Ace Excel 2 C18 PFP, 3μm, 2.1×150mm, maintained at 60°C. A 10mM ammonium formate containing 0.1% HCOOH and acetonitrile (100%) was used as mobile phase A and B, respectively. Mass transition, m/z 655.3→596.3 was selected to monitor CP-I and CP-III, while m/z 659.3→600.3 transition was used for the stable isotope labelled internal standard. Optimization of the liquid chromatography tandem mass spectrometry method ensured a lower limit of quantification (LLOQ) of 20pg/mL. Both CP-I and CP-III had extraction recoveries of 70%. The calibration range was 0.02-100ng/mL for both CP-I and CP-III, yielding calibration curves with correlation coefficients greater than 0.988. Inter day precision (CV<9%) and accuracy (84.3-103.9%) complied with the recommendation of the European Bioanalytical Forum. The optimized method was used to analyse plasma samples originating from three independent clinical studies. Obtained CP-I and CP-III plasma baseline levels in healthy volunteers were in good agreement with previously published data. Moreover, CP-I and CP-III plasma levels in human subjects dosed with a clinically confirmed OATP inhibitor were significantly increased compared to their baseline levels. These data demonstrate the potential of CP-I and CP-III as endogenous biomarkers to predict the drug-drug interaction (DDI) related to hepatic OATP1B inhibition. Stability of CP-I and CP-III in plasma and solvents under different processing and storage conditions was also evaluated.

Keywords: Coproporphyrin; Endogenous biomarker; Light stability; OATP1B; Oasis MAX SPE; sensitive LC–MS/MS.

MeSH terms

  • Biomarkers / blood*
  • Biomarkers / metabolism
  • Chromatography, Liquid / methods*
  • Coproporphyrins / blood*
  • Coproporphyrins / metabolism
  • Drug Interactions
  • Humans
  • Limit of Detection
  • Linear Models
  • Liver-Specific Organic Anion Transporter 1 / metabolism
  • Reproducibility of Results
  • Tandem Mass Spectrometry / methods*

Substances

  • Biomarkers
  • Coproporphyrins
  • Liver-Specific Organic Anion Transporter 1
  • SLCO1B1 protein, human
  • coproporphyrin III
  • coproporphyrin I